Crans Debbie C, Yang Lining, Haase Allison, Yang Xiaogai
Met Ions Life Sci. 2018 Feb 5;18. doi: 10.1515/9783110470734-015.
Vanadium compounds have been known to have beneficial therapeutic properties since the turn of the century, but it was not until 1965 when it was discovered that those effects could be extended to treating cancer. Some vanadium compounds can combat common markers of cancer, which include metabolic processes that are important to initiating and developing the phenotypes of cancer. It is appropriate to consider vanadium as a treatment option due to the similarities in some of the metabolic pathways utilized by both diabetes and cancer and therefore is among the few drugs that are effective against more than one disease. The development of vanadium compounds as protein phosphatase inhibitors for the treatment of diabetes may be useful for potential applications as an anticancer agent. Furthermore, the ability of vanadium to redox cycle is also important for biological properties and is involved in the pathways of reactive oxygen species. Early agents including vanadocene and peroxovanadium compounds have been investigated in detail, and the results can be used to gain a better understanding of how some vanadium compounds are modifying the metabolic pathways potentially developing cancer. Considering the importance of coordination chemistry to biological responses, it is likely that proper consideration of compound formulation will improve the efficacy of the drug. Future development of vanadium-based drugs should include consideration of drug formulation at earlier stages of drug development.
自世纪之交以来,钒化合物就被认为具有有益的治疗特性,但直到1965年才发现这些作用可以扩展到治疗癌症。一些钒化合物可以对抗癌症的常见标志物,这些标志物包括对癌症表型的启动和发展至关重要的代谢过程。由于糖尿病和癌症利用的一些代谢途径存在相似性,因此将钒视为一种治疗选择是合适的,它也是少数几种对多种疾病有效的药物之一。将钒化合物开发为用于治疗糖尿病的蛋白质磷酸酶抑制剂可能对其作为抗癌剂的潜在应用有用。此外,钒的氧化还原循环能力对其生物学特性也很重要,并且参与活性氧物种的途径。早期的药物包括二茂钒和过氧钒化合物已被详细研究,其结果可用于更好地理解一些钒化合物如何改变可能引发癌症的代谢途径。考虑到配位化学对生物反应的重要性,合理考虑化合物配方可能会提高药物的疗效。基于钒的药物的未来发展应包括在药物开发的早期阶段就考虑药物配方。